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Methods
Between 2000 and 2015, patients aged ≥18 years diagnosed with at least mild AS (aortic valve calcification with restricted systolic leaflet motion and an aortic valve area [AVA] <2 cm 2 ) and LVEF ≥50% were prospectively identified and included in an electronic database. The following patients were excluded: (1) individuals with more than mild aortic and mitral regurgitation; (2) patients with prosthetic valves, congenital heart disease (with the exception of bicuspid aortic valves), supravalvular or subvalvular AS, or dynamic left ventricular (LV) outflow tract obstruction, and (3) individuals who declined to participate in the study. The present analysis focused on 1140 patients with severe AS (defined as AVA ≤1 cm 2 or AVA normalized to body surface area [BSA] ≤0.6 cm 2 /m 2 , and Vmax ≥4 m/s). Patients were retrospectively divided into 4 groups according to baseline Vmax: group 1, patients with Vmax between 4 and 4.49 m/s; group 2, patients with Vmax between 4.5 and 4.99 m/s; group 3, patients with Vmax between 5 and 5.49 m/s; and group 4, patients with Vmax ≥5.5 m/s. We subsequently conducted subgroup analyses on the population of patients with no or minimal symptoms (n=558). Symptoms were ascertained by each patient's cardiologist. Patients with atypical chest pain and elderly patients with minimal dyspnea not clearly related to AS were considered to be minimally symptomatic. We calculated the Charlson comorbidity index for each patient, comprising the sum of the individual comorbidities. 7 The study had been approved by an independent ethic committee and was conducted in accordance with institutional policies, national legal requirements, and the revised Declaration of Helsinki.
Echocardiography
All patients underwent a comprehensive Doppler-echocardiographic assessment, using commercially available ultrasound systems. LV outflow tract was measured in a parasternal long-axis view, with a zoom on the aortic valve. The LV outflow tract's velocity time integral was recorded in an apical 5-chamber view. Aortic flow was systematically recorded using continuous wave Doppler in several views (apical 5-chamber, right parasternal, suprasternal, and epigastric). The view identifying the highest velocities was used to determine Vmax. In this view, 3 consecutive measurements were systematically averaged in patients in sinus rhythm and 5 in patients in atrial fibrillation. The alignment of both pulsed and continuous wave Doppler was optimized to be parallel with the flow. Pressure gradients were calculated using the simplified Bernoulli equation. 8 AVA was calculated using the continuity equation. 9 LV dimensions were assessed from parasternal long-axis views by 2-dimensional-guided M-mode using the leading edge methodology at end diastole and end systole. LVEF was calculated using Simpson biplane method. LV mass was estimated with an equation based on linear measurements normalized to BSA. 10 Left atrial volume was measured at LV end systole (using Simpson biplane method) and normalized to BSA. Systolic pulmonary artery pressure was calculated from the maximum peak tricuspid regurgitation velocity using the simplified Bernoulli equation.
Follow-Up
Median (interquartile range) follow-up was 38.0 (19-76) months. Patients were followed by clinical consultations and echocardiography in the outpatient clinics of the 2 tertiary centers. A few patients were followed in public hospitals or private practices by referring cardiologists working in collaboration with the tertiary centers. All surviving patients (n=838) had a minimum follow-up period of 2 years, and 761 (91%) of these patients had been followed up until the end of the study (2015 or 2016) . Events were ascertained by direct patient interview and clinical examination and by repeated follow-up letters, questionnaires, and telephone calls to physicians, patients, and (if necessary) next of kin. The end point of the study was all-cause mortality.
Statistical Analysis
SPSS software (version 18.0, IBM) was used for statistical analysis. Continuous variables were expressed as mean±SD or median (interquartile range), and categorical variables were expressed as counts and percentage. The relationship between continuous baseline variables and the various groups was explored using 1-way ANOVA (for normally distributed variables) or Kruskal-Wallis tests (for nonnormally distributed variables). Pearson χ 2 statistic or Fisher exact test was used to examine the association between categorical baseline variables and the various groups. The significance of the difference between the reference group (Vmax, 4-4.49 m/s) and the other groups was examined when a significant intergroup difference was observed. Interindividual differences were compared with a Mann-Whitney U test (with Bonferroni correction for multiple comparisons) and a Tukey test for normally distributed data. The start of follow-up for survival analysis was baseline echocardiography. Event rates±standard errors in the 4 groups were estimated using the Kaplan-Meier method and compared in 2-sided log-rank tests. Univariate and multivariable analyses of times to event were performed using Cox proportional hazards models with Vmax as an independent variable in a categorical format without use of model-building techniques. The following covariates considered to have a potential prognostic impact (on the basis of epidemiological data) were included: age, sex, BSA, hypertension, New York Heart Association class, coronary artery disease, history of atrial fibrillation, comorbidity index, LVEF, and aortic valve surgery (treated as a time-dependent covariate). Hazard ratios (HR) with their 95% confidence interval were estimated for all-cause mortality. The proportional hazards assumption was confirmed using statistics and graphs based on Schoenfeld residuals. For continuous variables, the assumption of linearity was assessed by plotting residuals against independent variables. Penalized smoothing splines (P-splines) were used to illustrate the association between Vmax as a continuous variable and the risk of mortality. Subgroup analyses (stratified by age, sex, coronary artery disease, hypertension, New York Heart Association class, atrial fibrillation, and BSA) were performed to determine the homogeneity of the association between high Vmax (≥5 m/s) and the outcome variable. We first estimated the effect of Vmax on the risk of overall mortality in each subgroup using a Cox univariate model, and then formally tested for first-order interactions in Cox models by entering interaction terms separately for each subgroup. The threshold for statistical significance was set to P<0.05. All tests were 2 tailed.
Results
Baseline Characteristics
The study population consisted of 1140 patients (men: 52%; mean age: 74 years; Table 1 ). Four hundred sixty patients had Vmax between 4 and 4.49 m/s (40%), 328 had Vmax between 4.5 and 4.99 m/s (29%), 220 had Vmax between 5 and 5.49 m/s (19%), and 132 had Vmax ≥5.5 m/s (12%). There were no intergroup differences in terms of age, sex, BSA, hemoglobin and creatinine levels, hypertension, diabetes mellitus, coronary artery disease, history of atrial fibrillation, or comorbidities.
As regard to echocardiographic variables (Table 1) 
Outcome Analyses
Eight hundred and thirty-four patients underwent AVR (including 99 using a transcatheter technique), and 199 (24%) had at least one associated coronary artery bypass graft. During follow-up, we recorded 302 deaths (26%). Sixty-two percent of deaths (n=187) occurred during follow-up of patients who had undergone AVR. Among the 115 patients who died before AVR, 48 (41%) had Vmax ≥5 m/s. Among the 332 patients with Vmax ≥5 m/s, 60 patients (18%) had a low flow state (index stroke volume <35 mL/m 2 ) and 29 of them (48%) died.
Association Between Vmax and Survival in the Overall Population
Six-year survival rate was 83±4% for patients with Vmax 4 to 4.49 m/s, 82±4% for patients with Vmax 4.5 to 4.99 m/s, 68±6% for patients with Vmax 5 to 5.49 m/s, and 66±6% for Figure 1B ) and after further adjustment for surgery (P<0.001 for both) compared with the reference group (Table 2) . However, there was no difference between Vmax 5 to 5.49 m/s and Vmax ≥5.5 m/s (P=0.62) even after covariate adjustment (P=0.93). By dividing the whole study population in 2 groups with a 5-m/s Vmax cutoff, the 6-year survival rate was 83±3% for patients with Vmax <5 m/s and 67±4% for patients with Vmax ≥5 m/s (log-rank P<0.001; Figure 2 ). In univariate Cox analysis, overall mortality was significantly higher for the Vmax ≥5 m/s group (P<0.001; The nature of the relationship between Vmax as continuous variable and the risk of mortality during follow-up was estimated using spline functions for Vmax (Figure 3) . The association between Vmax ≥5 m/s and risk of death was consistent in subgroups of patients with severe AS with no interactions between Vmax ≥5 m/s and any of the subgroups (Figure 4) 
Association Between Vmax and Survival in Asymptomatic or Minimally Symptomatic Patients
Five-year survival of asymptomatic or minimally symptomatic patients was 85±5% for Vmax 4 to 4.49 m/s, 92±5% for Vmax 4.5 to 4.99 m/s, 81±7% for Vmax 5 to 5.49 m/s, and 75±7% for Vmax ≥5.5 m/s (log-rank P, 0.16). Although there were no intergroup differences in univariate Cox analysis (P=0.36; Table 2 ), multivariable Cox analysis showed that overall mortality was different between the 4 groups (P=0.02; Table 2 ). There was no Table 2 ) even after covariate adjustment (P=0.85) and further adjustment for surgery (P=0.77; Table 2 ). In multivariable analysis, Vmax 5 to 5.49 m/s and Vmax ≥5.5 m/s exhibited significant excess mortality after covariate adjustment (P=0.018 and P=0.03, respectively) and after further adjustment for surgery (P=0.001 and P=0.04, respectively; Table 2 ) relative to Vmax 4 to 4.49 m/s. However, there was no difference between Vmax 5 to 5.49 m/s and patients with Vmax ≥5.5 m/s (P=0.324) even after covariate adjustment (P=0.57). When dividing the whole population into 2 groups with a 5-m/s Vmax cutoff, 5-year survival was 89±4% for patients with Vmax <5 m/s and 77±5% for patients with Vmax ≥5 m/s (log-rank P, 0.08; Figure 5A ). In multivariable analysis, Vmax ≥5 m/s exhibited significant excess mortality compared with Vmax <5 m/s after covariate adjustment (adjusted HR, 1.85 [1.25-2.71]; P=0.002; Figure 5B) 
Discussion
The present study of a large cohort of patients with severe AS and preserved LVEF provides strong evidence of the relationship between mortality and Vmax obtained by Doppler echocardiography. Both US and European guidelines consider that AVR is reasonable for asymptomatic patients with VSAS (class IIa recommendation) when the surgical risk is low. 4, 5 However, data on the relationship between mortality and Vmax are lacking. US guidelines define VSAS as Vmax ≥5 m/s, 5 whereas European guidelines use a different cutoff value (5.5 m/s). Therefore, the management of asymptomatic patients with Vmax between 5 and 5.5 m/s, which represent a significant proportion of patients with severe AS (≈20% in our study), remains debated. In the present study, almost one third of patients with severe AS had Vmax ≥5 m/s and only 12% Vmax ≥5.5 m/s. Our results show that Vmax ≥5 m/s strongly impacts survival in patients with severe AS. Furthermore, a Vmax cutoff ≥5 m/s is still predictive of mortality after adjustment for factors known to be major determinants of survival (including age, comorbidity, and aortic valve surgery). The fact that a higher Vmax cutoff value (ie, ≥5.5 m/s) does not imply additional risk shows that Vmax ≥5 m/s truly identifies AS patients with a high risk of death.
The management of asymptomatic severe AS remains subject to debate.
12,13 On one hand, asymptomatic patients with hemodynamically significant AS have high 2-year risk of meeting a composite end point (AVR or death). [14] [15] [16] On the other hand, the annualized rate of sudden death under medical management is estimated to be ≈1% per year in asymptomatic patients 17 and needs to be weighed up against the surgical mortality associated with AVR. 18 In contrast, it has been suggested that some patients with asymptomatic severe AS might be operated on too late in the course of the disease (ie, when myocardial impairment is [at least in part] irreversible), 16, 19 which results in a higher risk of mortality and heart failure reducing the long-term benefit of surgery. Ideally, AVR should be performed before the onset of irreversible left heart remodeling. 20 Consequently, the decision to perform AVR on asymptomatic patients requires a careful risk-benefit analysis.
In theory, AVA is the ideal indicator of severity of AS. Nevertheless, calculation of the AVA using the continuity equation is prone to errors; it is often difficult to measure the LV outflow tract's cross-sectional area because of the noncircular geometry or the presence of massive calcifications. 21 Furthermore, this measurement is operator dependent. Consequently, AVA measurement is generally considered to be less robust than Vmax-the cornerstone of AS severity assessment 6, 22, 23 as long as cardiac output is normal. Several studies have investigated the value of Vmax for risk stratification in patients with asymptomatic, severe AS. In a study of 622 asymptomatic patients with AS and Vmax ≥4 m/s, a Vmax ≥4.5 m/s was associated with an ≈50% increment in the risk of meeting a composite end point of AVR or death. 14 In a report on 116 asymptomatic patients with severe AS, peak aortic velocity >5.5 m/s was found to be associated with surgery/death rate of 56% at 1 year, 75% at 2 years, and 89% at 3 years. 2 Vmax was also shown to be an independent predictor of outcome in elderly patients. A recent study of 103 asymptomatic patients with severe AS aged >70 years reported that a Vmax ≥5 m/s was predictive of AVR or death. 24 These studies have undeniably validated Vmax as an outcome predictor in AS. However, the relationship between Vmax and survival per se has not been specifically investigated. Moreover, the cutoff for identifying high-risk patients remains unclear, as reflected by the different cutoffs for VSAS in the US and European guidelines. 4, 5 We deliberately chose not to use a composite end point that combines AVR and death because of the possible bias from the personal physician's assessment of disease severity. Hence, the present study focused on mortality.
Our results show that Vmax has a powerful prognostic impact on mortality. After adjustment for covariates of prognostic importance, Vmax ≥5 m/s was associated with >80% increase in the all-cause mortality during follow-up in asymptomatic and minimally symptomatic patients with severe AS and preserved LVEF. Furthermore, patients with Vmax ≥5.5 m/s had the same prognosis as those with Vmax between 5 and 5.5 m/s (accounting for 19% of the population). Therefore, Vmax ≥5 m/s truly identifies AS patients with a high risk of excess mortality. Although the current European Society of Cardiology guidelines define VSAS as corresponding to Vmax >5.5 m/s, 4 we think that a reduction in this threshold to 5.0 m/s (by analogy with US guidelines) 5 should be considered. In clinical practice, assessment of the severity of AS in asymptomatic patients should not rely on a single parameter but on a multiparameter approach that combine data derived from flow indices as peak transaortic velocities (or gradients which are similar) with less flow-dependent indices as AVA and indexed AVA. 25 Global longitudinal strain is useful in risk-stratifying patients with AS 26, 27 and could be a useful tool in the VSAS population. We can hypothesize that patients who are asymptomatic with Vmax ≥5 m/s could be further risk stratified on the basis of global longitudinal strain, thus providing clinicians with more robust tools to decide optimal timing of surgery in these patients. Unfortunately, we did not perform strain measurements in our patient population.
Limitations
As our follow-up data were obtained retrospectively, our study suffers from the inherent limitations of this type of analysis. The specific indications for surgery during follow-up which have been based on development of symptoms related to AS, a fall in LVEF, or an abnormal exercise test were not recorded in our database. Diagnosis and follow-up were performed by cardiologists with expertise in valvular heart disease, and surgical decisions were taken by the cardiology team with the approval of the patient's physician in accordance with current practice guidelines and with operative risk. The onset of symptoms related to AS which would have been an interesting additional end point was not recorded in our database. Indeed, if the rate of symptoms onset was higher in the 5 to 5.49 m/s group, but not even higher in the ≥5.5 m/s group, compared with the reference group, this would be an additional argument favoring the We chose to analyze a subgroup of patients with no or minimal symptoms because it is often difficult to differentiate between asymptomatic individuals and those with minimal symptoms in elderly patient populations. Some minimally symptomatic patients (ie, patients with atypical chest pain and elderly patients with minimal dyspnea not clearly related to AS) who in reality may have been symptomatic could have introduced a certain degree of bias into the study. However, in the subgroup of 225 asymptomatic patients, V max ≥5 m/s remained associated with a considerable excess mortality, even after adjustment for covariates of prognosis importance. Unfortunately, brain natriuretic peptid levels and stress testing data were not available on our database. Last, this study exclusively concerned patients with severe AS, preserved LVEF, and no significant valve regurgitation. Further studies are needed to evaluate the role of Vmax in other subsets of patients with severe AS.
Clinical Implication
The present study shows that Vmax ≥5 m/s is an independent predictor of mortality in patients with severe AS and preserved LVEF, irrespective of the functional status. Measurement of Vmax ≥5 m/s at the time of AS diagnosis is associated with at least a 60% increase in the risk of death during follow-up and an increase of at least 80% in asymptomatic patients. A higher threshold of Vmax (≥5.5 m/s) was not associated with a significantly worse prognosis. Our findings demonstrate that (1) Vmax assessment should be part of the decision-making process for surgery in asymptomatic or minimally symptomatic patients with severe AS, and (2) that a Vmax cutoff of 5 m/s clearly identifies patients at a high risk of excess mortality. Given the prior literature 2 and the results of the current study, clinicians should refer their minimally symptomatic or asymptomatic patients with severe AS and preserved LVEF for AVR in case of Vmax ≥5 m/s and low operative risk, as proposed by American College of Cardiology/American Heart Association guidelines (class IIa recommendation). 
